Abstract

Cannabis has been cultivated by man since Neolithic times. It was used, among others for fiber and rope production, recreational purposes and as an excellent therapeutic agent. The isolation and characterization of the structure of one of the main active ingredients of cannabis – Δ9 – tetrahydrocannabinol as well the discovery of its cannabinoid binding receptors CB1 and CB2, has been a milestone in the study of the possibilities of the uses of Cannabis sativa and related products in modern medicine. Many scientific studies indicate the potential use of cannabinoids in the fight against cancer. Experiments carried out on cell lines in vitro and on animal models in vivo have shown that phytocannabinoids, endocannabinoids, synthetic cannabinoids and their analogues can lead to inhibition of the growth of many tumor types, exerting cytostatic and cytotoxic neoplastic effect on cells thereby negatively influencing neo-angiogenesis and the ability of cells to metastasize.The main molecular mechanism leading to inhibition of proliferation of cancer cells by cannabinoids is apoptosis. Studies have shown, however, that the process of apoptosis in cells, treated with recannabinoids, is a consequence of induction of endoplasmic reticulum stress and autophagy. On the other hand, in the cellular context and dosage dependence, cannabinoids may enhance the proliferation of tumor cells by suppressing the immune system or by activating mitogenic factors. Leading from this there is a an obvious need to further explore cannabinoid associated molecular pathways making it possible to develop safe therapeutic drug agents for patients in the future.

References

• 1. Abrams D.I., Guzman M.: Cannabis in cancer care. Clin. Pharmacol.Ther., 2015; 97: 575‑586
  Google Scholar
• 2. Alexander A., Walker C.L.: The role of LKB1 and AMPK in cellularresponses to stress and damage. FEBS Lett., 2011; 585: 952‑957
  Google Scholar
• 3. Alexander S.P.: Therapeutic potential of cannabis‑related drugs.Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016; 64: 157‑166
  Google Scholar
• 4. Aredia F., Guamán Ortiz L.M., Giansanti V., Scovassi A.I.: Autophagyand cancer. Cells, 2012; 1: 520‑534
  Google Scholar
• 5. Armstrong J.L., Hill D.S., McKee C.S., Hernandez‑Tiedra S., LorenteM., Lopez‑Valero I., Anagnostou E.M., Babatunde F., CorazzariM., Redfern C.P., Velasco G., Lovat P.E.: Exploiting cannabinoid‑inducedcytotoxic autophagy to drive melanoma cell death. J. Invest.Dermatol., 2015; 135: 1629‑1637
  Google Scholar
• 6. Bifulco M., Laezza C., Gazzerro P., Pentimalli F.: Endocannabinoidsas emerging suppressors of angiogenesis and tumor invasion. Oncol.Rep., 2007; 17: 813‑816
  Google Scholar
• 7. Blázquez C., Carracedo A., Barrado L., Real P.J., Fernandez‑LunaJ.L., Velasco G., Malumbres M., Guzmán M.: Cannabinoid receptorsas novel targets for the treatment of melanoma. FASEB J., 2006; 20:2633‑2635
  Google Scholar
• 8. Blázquez C., Casanova M.L., Planas A., Gómez Del Pulgar T., VillanuevaC., Fernández‑Aceñero M.J., Aragonés J., Huffman J.W., JorcanoJ.L., Guzmán M.: Inhibition of tumor angiogenesis by cannabinoids.FASEB J., 2003; 17: 529‑531
  Google Scholar
• 9. Caffarel M.M., Sarrió D., Palacios J., Guzmán M., Sánchez C.: Δ9 tetrahydrocannabinolinhibits cell cycle progression in human breastcancer cells through Cdc2 regulation. Cancer Res., 2006; 66: 6615‑6621
  Google Scholar
• 10. Carracedo A., Gironella M., Lorente M., Garcia S., Guzmán M.,Velasco G., Iovanna J.L.: Cannabinoids induce apoptosis of pancreatictumor cells via endoplasmic reticulum stress‑related genes. CancerRes., 2006; 66: 6748‑6755
  Google Scholar
• 11. Carracedo A., Lorente M., Egia A., Blázquez C., Garcia S., GirouxV., Malicet C., Villuendas R.,.Gironella M., González‑Feria L.,Piris M.A., Iovanna J.L., Guzmán M., Velasco G.: The stress‑regulatedprotein p8 mediates cannabinoid‑induced apoptosis of tumor cells.Cancer Cell, 2006; 9: 301‑312
  Google Scholar
• 12. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovská A., Game P.,Wittert G.A.: The expression of receptors for endocannabinoids inhuman and rodent skeletal muscle. Biochem. Biophys. Res. Commun.,2007; 364: 105‑110
  Google Scholar
• 13. Chakravarti B., Ravi J., Ganju R.K.: Cannabinoids as therapeuticagents in cancer: current status and future implications. Oncotarget.,2014; 5: 5852‑5872
  Google Scholar
• 14. Chan P.C., Sills R.C., Braun A.G., Haseman J.K., Bucher J.R.: Toxicityand carcinogenicity of Δ9‑tetrahydrocannabinol in Fischer ratsand B6C3F1 mice. Fundam. Appl. Toxicol., 1996; 30: 109‑117
  Google Scholar
• 15. Cota D.: CB1 receptors: emerging evidence for central and peripheralmechanisms that regulate energy balance, metabolism, andcardiovascular health. Diabetes Metab. Res. Rev., 2007; 23: 507‑517
  Google Scholar
• 16. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C.,Schubert M., Auer D., Yassouridis A., Thöne‑Reineke C., Ortmann S.,Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., LutzB., Stalla G.K., Pagotto U.: The endogenous cannabinoid system affectsenergy balance via central orexigenic drive and peripherallipogenesis. J. Clin. Invest., 2003; 112: 423‑431
  Google Scholar
• 17. Cozzolino R., Cali G., Bifulco M. Laccetti P.: A metabolically stableanalogue of anandamide, Met‑F‑AEA, inhibits human thyroidcarcinoma cell lines by activation of apoptosis. Invest. New Drugs,2010; 28: 115‑123
  Google Scholar
• 18. Dando I., Donadelli M., Costanzo C., Dalla Pozza E., D’AlessandroA., Zolla L., Palmieri M.: Cannabinoids inhibit energetic metabolismand induce AMPK‑dependent autophagy in pancreatic cancer cells.Cell Death Dis., 2013; 4: e664
  Google Scholar
• 19. Dufey E., Sepúlveda D., Rojas‑Rivera D., Hetz C.: Cellular mechanismsof endoplasmic reticulum stress signaling in health anddisease. 1. An overview. Am. J. Physiol. Cell Physiol., 2014; 307:C582‑C594
  Google Scholar
• 20. Dziewulska A., Dobrzyń P., Dobrzyń A.: Rola kinazy białkowejaktywowanej przez AMP (AMPK) w regulacji metabolizmu mięśniszkieletowych. Postępy Hig. Med. Dośw., 2010; 64: 513‑521
  Google Scholar
• 21. Eskelinen E.L.: The dual role of autophagy in cancer. Curr. Opin.Pharmacol., 2011; 11: 294‑300
  Google Scholar
• 22. Folgi S., Breschi M.C.: The molecular bases of cannabinoid actionin cancer. Cancer Therapy, 2008; 6: 103‑116
  Google Scholar
• 23. Gaoni Y., Mechoulam R.: Isolation, structure and partial synthesisof an active constituent of hashish. J. Am. Chem. Soc., 1964;86: 1646‑1647
  Google Scholar
• 24. Glick D., Barth S., Macleod K.F.: Autophagy: cellular and molecularmechanisms. J. Pathol., 2010; 221: 3‑12
  Google Scholar
• 25. Grahame Hardie D.: AMP‑activated protein kinase: a key regulatorof energy balance with many roles in human disease. J. Intern.Med., 2014; 276: 543‑559
  Google Scholar
• 26. Gustafsson K., Christensson B., Sander B., Flygare J.: Cannabinoidreceptor‑mediated apoptosis induced by R(+)‑methanandamideand Win55,212‑2 is associated with ceramide accumulationand p38 activation in mantle cell lymphoma. Mol. Pharmacol., 2006;70: 1612‑1620
  Google Scholar
• 27. Guzmán M., Duarte M.J., Blázquez C., Ravina J., Rosa M.C.,Galve‑Roperh I., Sánchez C., Velasco G., González‑Feria L.: A pilotclinical study of Δ9‑tetrahydrocannabinol in patients with recurrentglioblastoma multiforme. Br. J. Cancer., 2006; 95: 197‑203
  Google Scholar
• 28. Hall W., Christie M., Currow D.: Cannabinoids and cancer: causation,remediation, and palliation. Lancet Oncol., 2005; 6: 35‑42
  Google Scholar
• 29. Hanahan D., Weinberg R.A.: Hallmarks of cancer: the next generation.Cell, 2011; 144: 646‑674
  Google Scholar
• 30. Hart S., Fischer O.M., Ullrich A.: Cannabinoids induce cancer cellproliferation via tumor necrosis factor α‑converting enzyme (TACE/ADAM17)‑mediated transactivation of the epidermal growth factorreceptor. Cancer Res., 2004; 64: 1943‑1950
  Google Scholar
• 31. Hegde V.L., Nagarkatti M., Nagarkatti P.S.: Cannabinoid receptoractivation leads to massive mobilization of myeloid‑derived suppressorcells with potent immunosuppressive properties. Eur. J.Immunol., 2010; 40: 3358‑3371
  Google Scholar
• 32. Hermanson D.J., Marnett L.J.: Cannabinoids, endocannabinoidsand cancer. Cancer Metastasis Rev., 2011; 30: 599‑612
  Google Scholar
• 33. Hoff P.M., Machado K.K.: Role of angiogenesis in the pathogenesisof cancer. Cancer Treat. Rev., 2012; 38: 825‑833
  Google Scholar
• 34. Iurlaro R., Muñoz‑Pinedo C.: Cell death induced by endoplasmicreticulum stress. FEBS J., 2016; 283: 2640‑2652
  Google Scholar
• 35. Jarosz P., Woźniak B.: Angiogeneza w chorobach nowotworowych.Przegląd Medyczny Uniwersytetu Rzeszowskiego i NarodowegoInstytutu Leków w Warszawie, 2012; 4: 498‑507
  Google Scholar
• 36. Kwolek G., Zakrzeska A., Kozłowska H., Malinowska B.: Wpływanandamidu, endogennego agonisty receptorów kannabinoidowychna układ krążenia. Postępy Hig. Med. Dośw., 2005; 59: 208‑218
  Google Scholar
• 37. Lakiotaki E., Giaginis C., Tolia M., Alexandrou P., Delladetsima I., Giannopoulou I., Kyrgias G., Patsouris E., Theocharis S.: Clinicalsignificance of cannabinoid receptors CB1 and CB2 expression inhuman malignant and benign thyroid lesions. Biomed. Res. Int.,2015; 2015: 839403
  Google Scholar
• 38. Lanz C., Mattsson J., Soydaner U., Brenneisen R.: Medicinal cannabis:in vitro validation of vaporizers for the smoke‑free inhalationof cannabis. PLoS One, 2016; 11: e0147286
  Google Scholar
• 39. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., DePetrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V.: Antitumoractivity of plant cannabinoids with emphasis on the effect ofcannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther.,2006; 318: 1375‑1387
  Google Scholar
• 40. Liu W.M., Fowler D.W., Dalgleish A.G.: Cannabis‑derived substancesin cancer therapy‑‑an emerging anti‑inflammatory role forthe cannabinoids. Curr. Clin. Pharmacol., 2010; 5: 281‑287
  Google Scholar
• 41. Lorente M., Carracedo A., Torres S., Natali F., Egia A., Hernández‑TiedraS., Salazar M., Blázquez C., Guzmán M., Velasco G.: Amphiregulinis a factor for resistance of glioma cells to cannabinoid‑inducedapoptosis. Glia, 2009; 57: 1374‑1385
  Google Scholar
• 42. Lorente M., Torres S., Salazar M., Carracedo A., Hernández‑TiedraS., Rodríguez‑Fornés F., García‑Taboada E., Meléndez B., MollejoM., Campos‑Martín Y., Lakatosh S.A., Barcia J., Guzmán M., Velasco G.:Stimulation of the midkine/ALK axis renders glioma cells resistant tocannabinoid antitumoral action. Cell Death Differ., 2011; 18: 959‑973
  Google Scholar
• 43. Lu T., Newton C., Perkins I., Friedman H., Klein T.W.: Cannabinoidtreatment suppresses the T‑helper cell‑polarizing function ofmouse dendritic cells stimulated with Legionella pneumophila infection.J. Pharmacol. Exp. Ther., 2006; 319: 269‑276
  Google Scholar
• 44. Madras B.K.: Update of cannabis and its medical use. WHO 37thECDD (2015) Agenda item 6.2
  Google Scholar
• 45. Mah L.Y., Ryan K.M.: Autophagy and cancer. Cold Spring Harb.Perspect. Biol., 2012; 4: a008821
  Google Scholar
• 46. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G.: Self‑eating andself‑killing: crosstalk between autophagy and apoptosis. Nat. Rev.Mol. Cell Biol., 2007; 8: 741‑752
  Google Scholar
• 47. McAllister S.D., Chan C., Taft R.J., Luu T., Abood M.E., Moore D.H.,Aldape K., Yount G.: Cannabinoids selectively inhibit proliferationand induce death of cultured human glioblastoma multiforme cells.,J. Neurooncol., 2005; 74: 31‑40
  Google Scholar
• 48. McKallip R.J., Nagarkatti M., Nagarkatti P.S.:Δ‑9‑tetrahydrocannabinol enhances breast cancer growth and metastasisby suppression of the antitumor immune response. J. Immunol.,2005; 174: 3281‑3289
  Google Scholar
• 49. Mizushima N.: The role of the Atg1/ULK1 complex in autophagyregulation. Curr. Opin. Cell Biol., 2010; 22: 132‑139
  Google Scholar
• 50. Motyka M., Marcinkowski J.T.: Używanie pochodnych konopi.Część II. Zastosowanie w medycynie vs. konsekwencje zdrowotne.Probl. Hig. Epidemiol., 2014; 95: 21‑27
  Google Scholar
• 51. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., CarchmanR.A.: Antineoplastic activity of cannabinoids. J. Natl. CancerInst., 1975; 55: 597‑602
  Google Scholar
• 52. Osei‑Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S.,Batkai S., Harvey‑White J., Mackie K., Offertaler L., Wang L., KunosG.: Endocannabinoid activation at hepatic CB1 receptors stimulatesfatty acid synthesis and contributes to diet‑induced obesity. J. Clin.Invest., 2005; 115: 1298‑1305
  Google Scholar
• 53. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di MarzoV., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K.,Mechoulam R., Ross R.A.: International Union of Basic and ClinicalPharmacology. LXXIX. Cannabinoid receptors and their ligands: beyondCB1 and CB2. Pharmacol. Rev., 2010; 62: 588‑631
  Google Scholar
• 54. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V.,Bifulco M.: Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signalsinvolved in angiogenesis and metastasis. FASEB J., 2003; 17: 1771‑1773
  Google Scholar
• 55. Proto M.C., Gazzerro P., Di Croce L., Santoro A., Malfitano A.M.,Pisanti S., Laezza C., Bifulco M.: Interaction of endocannabinoidsystem and steroid hormones in the control of colon cancer cellgrowth. J. Cell Physiol., 2012; 227: 250‑258
  Google Scholar
• 56. Radwan M.M., ElSohly M.A., El‑Alfy A.T., Ahmed S.A., Slade D.,Husni A.S, Manly S.P., Wilson L., Seale S., Cutler S.J., Ross S.A.: Isolationand pharmacological evaluation of minor cannabinoids fromhigh‑potency Cannabis sativa. J. Nat. Prod., 2015; 78: 1271‑1276
  Google Scholar
• 57. Ramer R., Hinz B.: New insights into antimetastatic and antiangiogeniceffects of cannabinoids. Int. Rev. Cell. Mol. Biol., 2015;314: 43‑116
  Google Scholar
• 58. Ramos J.A., Bianco F.J.: The role of cannabinoids in prostatecancer: basic science perspective and potential clinical applications.Indian J. Urol., 2012; 28: 9‑14
  Google Scholar
• 59. Russo E.B.: Taming THC: potential cannabis synergy and phytocannabinoid‑terpenoidentourage effects. Br. J. Pharmacol., 2011;163: 1344‑1364
  Google Scholar
• 60. Rutkowska M., Jamontt J.: Rola układu kannabinoidowego w fizjologiii patofizjologii ośrodkowego układu nerwowego. Adv. Clin.Exp. Med., 2005; 14: 1243‑1252
  Google Scholar
• 61. Sacewicz I., Wiktorska M., Wysocki T., Niewiarowska J.: Mechanizmyangiogenezy nowotworowej. Postępy Hig. Med. Dośw.,2009; 63: 159‑168
  Google Scholar
• 62. Salazar M., Carracedo A., Salanueva I.J., Hernández‑Tiedra S.,Egia A., Lorente M., Vázquez P., Torres S., Iovanna J.L., Guzmán M.,Boya P., Velasco G.: TRB3 links ER stress to autophagy in cannabinoidanti‑tumoral action. Autophagy, 2009; 5: 1048‑1049
  Google Scholar
• 63. Salazar M., Carracedo A., Salanueva I.J., Hernandez‑Tiedra S.,Lorente M., Egia A., Vázquez P., Blázquez C., Torres S., García S.,Nowak J., Fimia G.M., Piacentini M., Cecconi F., Pandolfi P.P. i wsp.:Cannabinoid action induces autophagy‑mediated cell death throughstimulation of ER stress in human glioma cells. J. Clin. Invest., 2009;119: 1359‑1372
  Google Scholar
• 64. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H.: Cannabinoidsfor cancer treatment: progress and promise. Cancer Res.2008; 68: 339‑342
  Google Scholar
• 65. Sarfaraz S., Afaq F., Adhami V.M., Malik A., Mukhtar H.: Cannabinoidreceptor agonist‑induced apoptosis of human prostate cancercells LNCaP proceeds through sustained activation of ERK1/2leading to G1 cell cycle arrest. J. Biol. Chem., 2006; 281: 39480‑39491
  Google Scholar
• 66. Sarnowska E., Balcerak A., Olszyna‑Serementa M., Kotlarek D.,Sarnowski T.J., Siedlecki J.A.: Kinaza białkowa aktywowana przezAMP (AMPK) jako cel terapeutyczny. Postępy Hig. Med. Dośw., 2013;67: 750‑760
  Google Scholar
• 67. Shackelford D.B. Shaw R.J.: The LKB1‑AMPK pathway: metabolismand growth control in tumor suppression. Nat. Rev. Cancer,2009; 9: 563‑575
  Google Scholar
• 68. Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A.: Cannabidiolinduces programmed cell death in breast cancer cells bycoordinating the cross‑talk between apoptosis and autophagy. Mol.Cancer Ther., 2011; 10: 1161‑1172
  Google Scholar
• 69. Torres S., Lorente M., Rodríguez‑Fornés F., Hernández‑TiedraS., Salazar M., García‑Taboada E., Barcia J., Guzmán M., Velasco G.:A combined preclinical therapy of cannabinoids and temozolomideagainst glioma. Mol. Cancer Ther., 2011; 10: 90‑103
  Google Scholar
• 70. Vara D., Salazar M., Olea‑Herrero N., Guzmán M., Velasco G.,Diaz‑Laviada I.: Anti‑tumoral action of cannabinoids on hepatocellularcarcinoma: role of AMPK‑dependent activation of autophagy.Cell Death Differ., 2011; 18: 1099‑1111
  Google Scholar
• 71. Velasco G., Galve‑Roperh I., Sánchez C., Blazquez C., HaroA., Guzmán M.: Cannabinoids and ceramide: two lipids acting hand‑by‑hand. Life Sci., 2005; 77: 1723‑1731
  Google Scholar
• 72. Velasco G., Hernández‑Tiedra S., Dávila D., Lorente M.: The useof cannabinoids as anticancer agents. Prog. Neuropsychopharmacol.Biol. Psychiatry, 2016; 64: 259‑266
  Google Scholar
• 73. Velasco G, Sánchez C., Guzmán M.: Endocannabinoids and cancer.W: Endocannabinoids, Handbook of Experimental Pharmacology.Pertwee R.G. (red.), 2015, pp 449‑469
  Google Scholar
• 74. Velasco G., Sánchez C., Guzmán M.: Anticancer mechanisms ofcannabinoids. Curr. Oncol., 2016; 23: S23‑S32
  Google Scholar
• 75. Velasco G., Sánchez C., Guzmán M.: Towards the use of cannabinoidsas antitumour agents. Nat. Rev. Cancer, 2012; 12: 436‑444
  Google Scholar
• 76. Vemuri V.K., Makriyannis A.: Medicinal chemistry of cannabinoids.Clin. Pharmacol. Ther., 2015; 97: 553‑558
  Google Scholar
• 77. Yadav R.K., Chae S.W., Kim H.R., Chae H.J.: Endoplasmic reticulumstress and cancer. J. Cancer Prev., 2014; 19: 75‑88
  Google Scholar
• 78. Zhu L.X., Sharma S., Stolina M., Gardner B., Roth M.D., TashkinD.P., Dubinett S.M.: Δ‑9‑tetrahydrocannabinol inhibits antitumorimmunity by a CB2 receptor‑mediated, cytokine‑dependent pathway.J. Immunol., 2000; 165: 373‑380
  Google Scholar
• 79. Zuardi A.W.: History of cannabis as a medicine: a review. Rev.Bras. Psiquiatr., 2006; 28: 153‑157
  Google Scholar

Full text